Pentixapharm Holding AG (XTER:PTP) Ending Cash Position: €5.16 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:PTP Pentixapharm Holding AG XTER:PTP
20 GF Score
Price €2.03
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG Ending Cash Position?

Pentixapharm Holding AG XTER:PTP -2.40% 20 Ending Cash Position is €5.16 Mil as of Mar. 2026. GuruFocus rates XTER:PTP with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Pentixapharm Holding AG's Ending Cash Position for the quarter that ended in Mar. 2026 was €5.16 Mil.

Pentixapharm Holding AG's quarterly Ending Cash Position declined from Sep. 2025 (€6.97 Mil) to Dec. 2025 (€4.62 Mil) but then increased from Dec. 2025 (€4.62 Mil) to Mar. 2026 (€5.16 Mil).

Pentixapharm Holding AG's annual Ending Cash Position increased from Dec. 2023 (€9.70 Mil) to Dec. 2024 (€23.23 Mil) but then declined from Dec. 2024 (€23.23 Mil) to Dec. 2025 (€4.62 Mil).

Pentixapharm Holding AG Ending Cash Position Related Terms

Pentixapharm Holding AG Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG Ending Cash Position Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
2.39 1.09 9.70 23.23 4.62

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 17.39 14.21 6.97 4.62 5.16
XTER:PTP
20GF Score
Pentixapharm Holding AG XTER:PTP
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pentixapharm Holding AG's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=23.232+-18.608
=4.62

Pentixapharm Holding AG's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.63+0.533
=5.16

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €5.16 Mil mean?
Pentixapharm Holding AG (XTER:PTP) has a Ending Cash Position of €5.16 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's Ending Cash Position too high?
Pentixapharm Holding AG's current Ending Cash Position is €5.16 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Ending Cash Position compare to VRTX and REGN?
Pentixapharm Holding AG's Ending Cash Position of €5.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current Ending Cash Position is €5.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current Ending Cash Position of €5.16 Mil. The current Ending Cash Position is €5.16 Mil. Pentixapharm Holding AG's overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current Ending Cash Position is €5.16 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
20GF Score

Get the complete analysis for XTER:PTP

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.03
Price